Literature DB >> 22336636

Ischemia modified albumin: an oxidative stress marker in β-thalassemia major.

Samir M Awadallah1, Manar F Atoum, Nisreen A Nimer, Suleiman A Saleh.   

Abstract

BACKGROUND: Ischemia modified albumin (IMA) is an altered type of serum albumin that forms under conditions of oxidative stress. This study reports on the levels and clinical significance of IMA in patients with β-thalassemia major.
METHODS: Blood specimens were collected from 166 subjects (101 β-thalassemia major patients and 65 healthy controls). Serum levels of IMA, ferritin, malondialdehyde (MDA), ferroxidase, transaminases, total protein, and albumin were determined using conventional methods.
RESULTS: Serum levels of IMA (ABSU) were significantly higher in patients than in controls (0.725±0.155 vs 0.554±0.154, p=0.000). Similarly, higher levels were also observed for ferritin, MDA, ferroxidase, and transaminases. No significant differences were observed between patients and controls with respect to total protein and albumin. Spearman univariate analysis demonstrated significant correlation between IMA and ferritin, MDA, ferroxidase, and transaminases. Multiple linear regression analysis revealed significant association of IMA with ferritin and ferroxidase after adjusting for the other variables (r=0.343, p=0.002; r=0.228, p=0.029 respectively). MDA however, correlated significantly with ferritin only (r=0.654, p=0.000).
CONCLUSION: Our findings suggest that increased levels of IMA in thalassemic patients are likely to be a result of iron-induced oxidative stress and hence its potential significance as a new marker of oxidative stress in such patients.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22336636     DOI: 10.1016/j.cca.2012.01.037

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.

Authors:  Amira Abdel Moneam Adly; Nayera Hazaa Khalil ElSherif; Eman Abdel Rahman Ismail; Yosra Abdelzaher Ibrahim; Gamal Niazi; Sara Hamed Elmetwally
Journal:  Redox Rep       Date:  2017-03-13       Impact factor: 4.412

2.  Investigation of the Possibility of Using Serum Ischemia Modified Albumin (IMA) as a Novel and Early Marker of the Extent of Oxidative Stress Induced by Various Tobacco Products.

Authors:  Pavan R Gothe; Maji Jose; Vinitha R Pai; Sindhu Harish; Jyothi D'Souza; Vishnudas Prabhu
Journal:  J Clin Diagn Res       Date:  2015-11-01

3.  The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β- thalassemia major.

Authors:  Soheila Setoodeh; Marjan Khorsand; Mohammad Ali Takhshid
Journal:  J Diabetes Metab Disord       Date:  2020-06-03

Review 4.  An Overview of Celiac Disease in Childhood Type 1 Diabetes.

Authors:  Iraj Shahramian; Ali Bazi; Alireza Sargazi
Journal:  Int J Endocrinol Metab       Date:  2018-06-27

5.  Assessment of thiol/disulfide balance as an oxidative stress marker in children with β-thalassemia major.

Authors:  Ahmet Guzelcicek; Gokhan Cakirca; Ozcan Erel; Abdullah Solmaz
Journal:  Pak J Med Sci       Date:  2019 Jan-Feb       Impact factor: 1.088

6.  Ischemia-modified albumin must be evaluated as an oxidative stress marker together with albumin and bilirubin in individuals with acute appendicitis.

Authors:  Varikasuvu Seshadri Reddy; Balananda Perugu; Mohinder Kumar Garg
Journal:  Clinics (Sao Paulo)       Date:  2015-07-01       Impact factor: 2.365

7.  Evaluation of an educational intervention based on health belief model on beta thalassemia carrier and final suspects couples.

Authors:  Nourdin Saeedi Kia; Khdabaakhsh Karami; Hashem Mohamadian; Amal Saki Malehi
Journal:  J Educ Health Promot       Date:  2018-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.